Rasio Therapeutics
Computer-aided drug design for novel oncology therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | $1.5m | Seed | |
| Total Funding | 000k | ||
Related Content
Rasio Therapeutics is a biopharmaceutical company founded in 2019 that focuses on developing new medicines for oncology through computer-aided drug design. The company, which originated as a spin-off from SilcsBio, LLC, utilizes a proprietary platform with algorithms to identify new binding areas on therapeutic targets related to cancer. This technology-driven approach is intended to accelerate the creation of drugs for unmet medical needs.
The firm operates in the drug discovery and biotechnology sectors, with a specific focus on oncology. Its business model centers on leveraging its computational platform for in-house drug development and forming strategic partnerships with larger pharmaceutical companies. Rasio Therapeutics has secured collaborations with entities such as Novartis, Lantheus, and Merck. The company has raised capital through various funding rounds, including a grant in 2019 and a seed round in 2021, totaling $1.5 million from investors like the National Foundation of Cancer Research, AIM-HI Accelerator Fund, Early Charm Ventures, and BlueDot.
The company's platform aims to provide a highly detailed understanding of drug-target interactions, allowing researchers to concentrate on advancing novel therapies. By using its computational tools to design molecules that fit specific biological targets, Rasio works to enhance potential treatments for cancer and other diseases.
Keywords: drug discovery, computational chemistry, oncology therapeutics, computer-aided drug design, biopharmaceutical, cancer research, drug development, biotechnology, novel medicines, oncology targets, molecular modeling, pharmaceutical industry, binding regions, preclinical development